Geoffrey Y. Ku, MD

Geoffrey Ku, MD, discusses data from HERIZON-GEA-01 showing zanidatamab plus tislelizumab benefits patients with HER2-positive GEA regardless of PD-L1 status.

Geoffrey Y. Ku, MD, medical oncologist, discusses the efficacy of zanidatamab plus standard chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma in the ongoing phase 2 ZW25-201 trial.

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of durvalumab in the treatment of patients with gastric cancer.

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.